Skåne University Hospital
Lund, Skåne County, 22242, Sweden
NCT Number: NCT04427956
Three different protocols for inducing corneal crosslinks in subjets with progressive keratoconus will be evaluated in this randomised clinical study.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Lund, Skåne County, 22242, Sweden
Riboflavin does not penetrate the intact corneal epithelium. Corneal cross linking (CXL) is typically performed using the so-called "Dresden protocol". The Dresden protocol states 30 minutes of UVA-radiation (3mW/cm2) but a 10 minute irradiation protocol (9mW/cm2) is frequently used. Both of the protocols involve mechanical removal of the epithelium over the central 8 mm of the corneal surface. The first days after treatment therefore involves some degree of pain, often intense, and the presence of a healing epithelial defect may be associated with development of infiltrates in the cornea. A number of approaches have been evaluated in order to promote riboflavin penetration through the intact epithelium, of which iontophoresis appears most promising. Keratoconic corneas are thin at the cone location and sometimes it is difficult to maintain the safety margin of 400 microns during corneal crosslinking. Instead of using isotonic standard riboflavin, a swelling effect of the cornea can be obtained by using hypotonic riboflavin. However, the latter has been indicated as less effective in the process of inducing cross links.
Eighty-one of 81 patients of various degrees of keratoconus will be randomised to one of the following groups: 1) CXL (UVA 9mW/cm2) using isotonic riboflavin, or 2) CXL (UVA 9mW/cm2) using hypotonic riboflavin or 3) Iontophoresis with Ricrolin with following CXL (UVA 9mW/cm2).
Hypothesis:
i) CXL with hypotonic riboflavin or CXL with Ricrolin administered by iontophoresis or CXL with isotonic riboflavin is non-inferior compared to standard CXL with isotonic riboflavin.
ii) The morphological structure post-CXL in the three different groups will be similar without any significant differences.
The iontophoresis-assisted treatment arm has been interrupted due to low efficacy in halting disease progression. The results have been published.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.
CXL protocol with isotonic riboflavin
CXL protocol with hypotonic riboflavin
CXL protocol with iontophoresis and ricrolin
Time frame: Patients will be evaluated 1, 6, 12 and 24 months after treatment.
Uncorrected visual acuity (UCVA) and best spectacle corrected visual acuity (BSCVA)
Time frame: Patients will be evaluated 1, 6, 12 and 24 months after treatment.
Maximum corneal steepness
Time frame: Patients will be evaluated 1, 6, 12 and 24 months after treatment.
Corneal astigmatism
Time frame: Confocal microscopy will be performed at 6 and 12 months.
Corneal nerve cell density will be evaluated using confocal microscopy
Time frame: Confocal microscopy will be performed at 6 and 12 months.
Keratocyte cell density will be evaluated using confocal microscopy
Time frame: Confocal microscopy will be performed at 6 and 12 months.
Endothelial cell count will be evaluated using confocal microscopy
Time frame: Confocal microscopy will be performed at 6 and 12 months.
Identification of the demarcation lines with confocal microscopy will help establishing how deep was the effect of the CXL treatment.
Time frame: Corneal pachymetry will be evaluated before and then every 5 minutes during 30 minutes under CXL treatment.
Corneal pachymetry is the process of measuring the thickness of the cornea
Region Skane
Other
Prospective Randomised Corneal Crosslinking Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03442751
Progressive Keratoconus
Waltham, Massachusetts, United States
View Trial DetailsNCT00647699
Corneal Diseases, Eye Diseases
La Jolla, California, United States
View Trial DetailsNCT04504578
Progressive Keratoconus
Cairo, Egypt
View Trial DetailsNCT02117999
Progressive Keratoconus
Rome, Italy
View Trial Details